Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Recurrent Follicular LymphomaRefractory Follicular Lymphoma

Interventions

DRUG

Bendamustine Hydrochloride

Given IV

DRUG

Brentuximab Vedotin

Given IV

Trial Locations (1)

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Seagen Inc.

INDUSTRY

lead

Joseph Tuscano

OTHER